PDS Biotechnology Corp. (PDSB)

Over the past six months, PDS Biotechnology Corp.'s stock price has been impacted by several events. In November 2025, the company reported positive translational data for PDS0101 and conducted a registered direct offering, while Q3 results highlighted strong VERSATILE-002 survival data but also ongoing losses. In December 2025, PDS Biotech secured a Type C FDA meeting and expanded patent protection for PDS0101 in Japan. In January 2026, the stock surged after the company submitted an amended protocol to the FDA for its Phase 3 VERSATILE-003 clinical trial and announced a new U.S. patent covering the technology underlying PDS0101. The company also reported preliminary results from a National Cancer Institute-led Phase 2 study of its PDS01ADC in prostate cancer. As of February 7, 2026, the stock has experienced a significant decline.

There is no specific information indicating demand seasonality for PDS Biotechnology Corp.'s products and services. The demand for its products is primarily driven by the prevalence of the diseases they aim to treat and the progress and success of their clinical trials, rather than seasonal consumer patterns.

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies and infectious disease vaccines, utilizing its Versamune® platform to activate the immune system's T-cells. Its lead product candidate, Versamune® HPV (PDS0101), is in Phase II clinical trials for HPV-associated cancers and is being developed with immune checkpoint inhibitors. Other product candidates include PDS0102 for acute myeloid leukemia, prostate, and breast cancer; PDS0103 for ovarian, breast, colorectal, and lung cancers; PDS01ADC, an Interleukin 12 fused antibody-drug conjugate; and PDS0202, an influenza vaccine. Preliminary results from a Phase 2 study of PDS01ADC in metastatic castration-resistant prostate cancer were presented in January 2026.

PDS Biotechnology Corporation is based in Princeton, New Jersey, United States. The company's operations and clinical trials primarily take place in the United States and the European Union.

In the past year, PDS Biotechnology's stock has underperformed both the US Biotechs industry and the broader US market. Short interest in PDS Biotechnology has recently increased, indicating a decreasing investor sentiment. While there have been positive developments in clinical trials and patent allowances, the stock's performance and increased short interest suggest a challenging period for investor perception.

PDS Biotechnology Corporation has 56 institutional owners and shareholders holding a total of 5,686,701 shares, with major institutional owners including Vanguard Group Inc and BlackRock, Inc. INSPIRION WEALTH ADVISORS, LLC held the largest institutional position as of December 2025. Institutional ownership collectively represents 11.47% of the stock. Individual insider ownership accounts for 24.13% of the stock, with James Healy being the largest individual shareholder.